ARTICLE | Clinical News
Pharmos discloses LE-T delay
July 11, 2001 7:00 AM UTC
PARS and partner Bausch & Lomb said that Phase III testing of LE-T, a combination of the corticosteroid loteprednol etabonate with the anti-infective tobramycin, will require enrollment of about 2,400...